Navigation Links
Array BioPharma To Present At The Wells Fargo Securities Research And Economics 2013 Healthcare Conference
Date:6/13/2013

BOULDER, Colo., June 13, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference in Boston.  The public is welcome to participate in the conference through a webcast on the Array BioPharma website.(Logo:  http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)Event:Wells Fargo Securities Research and Economics 2013 Healthcare ConferencePresenter:Ron Squarer, Chief Executive OfficerDate:Wednesday, June 19, 2013Time:9:15 a.m. Eastern Time Location:InterContinental Hotel,  Boston, MAWebcast:www.arraybiopharma.comAbout Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis expects to begin Phase 3 trials evaluating Array-invented MEK162 in NRAS-mutant melanoma and in BRAF-mutant melanoma in 2013.  In addition, Array will begin a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis in 2013.  AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer during the second half of 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

CONTACT:

Tricia HaugetoArray BioPharma Inc.303-386-1193thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Array BioPharma Announces Exercise Of Underwriters Option To Purchase An Additional $17.25 Million Of 3.00% Convertible Senior Notes
2. New Date And Time For Array BioPharma Presentation At The Jefferies 2013 Global Healthcare Conference
3. Array BioPharma Announces Proposed Public Offering of Convertible Debt
4. Two Array Invented MEK Inhibitors Showcased At ASCO
5. Array BioPharma To Present At The Jefferies 2013 Global Healthcare Conference
6. Oncothyreon and Array Announce Collaboration to Develop and Commercialize anti-HER2 Compound ARRY-380
7. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
8. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
9. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
10. New Versa HD System Tops Elektas Comprehensive Array of Cancer Management Solutions at 2nd ESTRO Forum
11. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 According ... Share, Development, Growth and Demand Forecast to 2022 - ... Pump and Others)" published by P&S Market Research, the ... million in 2015, and it is expected to grow ... type, the insulin pump segment is expected to witness ...
(Date:5/25/2016)... SOUTHLAKE, Texas , May 25, 2016 /PRNewswire/ ... today the issuance to it by the US ...  9,218,608. The company,s technology includes proprietary processes for ... claims for health and wellness programs, HIPAA compliance ... "Our ...
(Date:5/25/2016)... ReportsnReports.com adds "Chronic Cough ... provides an overview on therapeutic pipeline of Chronic ... therapeutics assessment by drug target, mechanism of action ... along with latest updates, and featured news and ... in the therapeutic development for Chronic Cough and ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 26, 2016 , ... Georgia State University College of Law ... , Answering to the increasing demand for curricular specializations, the Certificate in Intellectual ... and land use law. ,  , “The demand for lawyers with specific knowledge ...
(Date:5/26/2016)... ... ... The Woodlands at John Knox Village , Florida’s first Life Plan ... and healing, celebrated its grand opening, today. The Woodlands at John Knox Village is ... Staff. , “This is an incredibly fulfilling time for John Knox Village as we ...
(Date:5/26/2016)... ... 26, 2016 , ... MadgeTech will be showcasing its line of data ... Hampshire at the MadgeTech headquarters. With products sold in more than 100 countries around ... including NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech ...
(Date:5/26/2016)... ... ... An April Gallup survey found rising health care costs to be the ... Senior Living (SHSL) may not share those same worries thanks to a new ... year, while holding the line on increasing their contributions, including premiums, deductibles and the ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
Breaking Medicine News(10 mins):